Mesenchymal stem cells alleviate mouse liver fibrosis by inhibiting pathogenic function of intrahepatic B cells
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Background and Aims: The immunomodulatory characteristics of mesenchymal stem cells (MSCs) make them a promising therapeutic approach for liver fibrosis (LF). Here, we postulated that MSCs could potentially suppress the pro-fibrotic activity of intrahepatic B cells, thereby inhibiting LF progression. Approach and Results: Administration of MSCs significantly ameliorated LF as indicated by reduced myofibroblast activation, collagen deposition, and inflammation. The treatment efficacy of MSCs can be attributed to decreased infiltration, activation, and pro-inflammatory cytokine production of intrahepatic B cells. Single-cell RNA sequencing revealed a distinct intrahepatic B cell atlas, and a subtype of naive B cells (B-II) was identified, which were markedly abundant in fibrotic liver, displaying mature features with elevated expression of several proliferative and inflammatory genes. Transcriptional profiling of total B cells revealed that intrahepatic B cells displayed activation, proliferation, and pro-inflammatory gene profile during LF. Fibrosis was attenuated in mice ablated with B cells (μMT) or in vivo treatment with anti-CD20. Moreover, fibrosis was recapitulated in μMT after adoptive transfer of B cells, which in turn could be rescued by MSC injection, validating the pathogenic function of B cells and the efficacy of MSCs on B cell-promoted LF progression. Mechanistically, MSCs could inhibit the proliferation and cytokine production of intrahepatic B cells through exosomes, regulating the Mitogen-activated protein kinase and Nuclear factor kappa B signaling pathways. Conclusions: Intrahepatic B cells serve as a target of MSCs, play an important role in the process of MSC-induced amelioration of LF, and may provide new clues for revealing the novel mechanisms of MSC action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Burden of liver diseases in the world
Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.014 · Cited by 3,783
Ren, G., Zhang, L., Zhao, X., Xu, G., Zhang, Y., Roberts, A. I., Zhao, R. C., & Shi, Y. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2007.11.014 · Cited by 2,101
Fibrosis: from mechanisms to medicines
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020) · Nature · doi:10.1038/s41586-020-2938-9 · Cited by 1,868 · cited 1×
“[28] It is well known that LF is a dynamic process that can be effectively reversed, and modulating the liver immune micro-environment is considered a therapeutic strategy for LF. [29] A large amount of preclinical evidence has shown that MSC treatment can improve LF and we also found that MSC…”
Kitamura, D., Roes, J., Kühn, R., & Rajewsky, K. (1991) · Nature · doi:10.1038/350423a0 · Cited by 1,783
Human mesenchymal stem cells modulate B-cell functions
Corcione, A., Benvenuto, F., Ferretti, E., Giunti, D., Cappiello, V., Cazzanti, F., Risso, M., Gualandi, F., Mancardi, G. L., Pistoia, V., et al. (2006) · Blood · doi:10.1182/blood-2005-07-2657 · Cited by 1,767
Macrophage heterogeneity in liver injury and fibrosis
Tacke, F., & Zimmermann, H. W. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.025 · Cited by 1,061 · cited 1×
“[5] Other immune cells such as macrophages, [6 – 8] natural killer T cells, [9,10] CD4 + T cells, [10,11] and dendritic cells [12] play dual roles (pro-fibrotic and anti-fibrotic responses) in both HSC activation and LF.”
Ramachandran, P., Pellicoro, A., Vernon, M. A., Boulter, L., Aucott, R. L., Ali, A., Hartland, S. N., Snowdon, V. K., Cappon, A., Gordon-Walker, T. T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119964109 · Cited by 1,001 · cited 1×
“[5] Other immune cells such as macrophages, [6 – 8] natural killer T cells, [9,10] CD4 + T cells, [10,11] and dendritic cells [12] play dual roles (pro-fibrotic and anti-fibrotic responses) in both HSC activation and LF.”
Hepatic inflammatory responses in liver fibrosis
Hammerich, L., & Tacke, F. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00807-x · Cited by 803 · cited 1×
“…a dynamic process that can be effectively reversed, and modulating the liver immune micro-environment is considered a therapeutic strategy for LF. [29] A large amount of preclinical evidence has shown that MSC treatment can improve LF and we also found that MSC treatment has the potential to…”
Karlmark, K. R., Weiskirchen, R., Zimmermann, H. W., Gassler, N., Ginhoux, F., Weber, C., Merad, M., Luedde, T., Trautwein, C., & Tacke, F. (2009) · Hepatology · doi:10.1002/hep.22950 · Cited by 782
Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair
Shi, Y., Hu, G., Su, J., Li, W., Chen, Q., Shou, P., Xu, C., Chen, X., Huang, Y., Zhu, Z., et al. (2010) · Cell Research · doi:10.1038/cr.2010.44 · Cited by 575 · cited 1×
“[31] In this study, MSCs significantly inhibited B-cell function during LF through the reduction of B-cell infiltration, inhibition of their activation, and suppression of pro-inflammatory gene expression.”
Cited by
Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy
(2024) · doi:10.1146/annurev-pharmtox-020524-012013 · Cited by 64
Shi, L., Zhang, Z., Mei, S., Wang, Z., Xu, Z., Yao, W., Liu, L., Yuan, M., Pan, Y., Zhu, K., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02318-4 · Cited by 16
Cell therapy for end-stage liver disease: Current state and clinical challenge
Zhang, L., Deng, Y., Bai, X., Wei, X., Ren, Y., Chen, S., & Deng, H. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003332 · Cited by 12
“[125] Additionally, the MSC-mediated inhibitory effect on the maturation of circulating monocytes and DCs depends on IL6 and HGF. [126,127] Moreover, evidence suggests that the inhibitory effect of MSCs on NK cells is attributed to PGE2, IDO, TGF-β 1, and NO secreted by MSCs. [128] Interestingly,…”
Extracellular vesicles: emerging therapeutic agents for liver fibrosis
Chiabotto, G., Semnani, A., Ceccotti, E., & Bruno, S. (2025) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2025.08 · Cited by 13
Fang, Y., Chen, L., Yuan, Y., Zhou, S., Fu, J., Zhang, Q., Zhang, N., Huang, Y., Li, Y., Yuan, L., et al. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04351-0 · Cited by 5
“MSC-based cell therapies have been reported to prevent the progress of hepatic fibrosis and improve liver function [28, 29].”
Metadata
- Authors
- Feng, X., Feng, B., Zhou, J., Yang, J., Pan, Q., Yu, J., Shang, D., Li, L., & Cao, H.
- Venue
- Hepatology
- Published
- 2024-03-28
- Volume
- 81
- Issue
- 4
- Pages
- 1211-1227
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W4393257605
- Cited by
- 60
- References
- 20
- FWCI
- 13.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mesenchymal stem cells alleviate mouse liver fibrosis by inhibiting pathogenic function of intrahepatic B cells. https://app.cochat.ai/papers/10.1097/hep.0000000000000831
- The paper
- Feng, X., Feng, B., Zhou, J., Yang, J., Pan, Q., Yu, J., Shang, D., Li, L., & Cao, H. (2025). Mesenchymal stem cells alleviate mouse liver fibrosis by inhibiting pathogenic function of intrahepatic B cells. Hepatology. https://doi.org/10.1097/hep.0000000000000831
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.